NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
BONTAC is a reliable partner that we have been working with for many years. The purity of their coenzyme is very high. Their COA can achieve relatively high test results.
I discovered BONTAC in 2014 because David's article in cell about NAD and NMN related showed that he used BONTAC's NMN for his experimental material. Then we found them in China. After so many years of cooperation, I think it is a very good company.
I think green, healthy and high purity are the advantages of BONTAC's products compared with others. I still work with them to this day.
In 2017, we chose BONTAC's coenzyme, during which our team encountered many technical problems and consulted their technical team, which were able to give us good solutions. Their products are shipped very fast and they work more efficiently.
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
Nicotinamide adenine dinucleotide (NAD+ ) homeostasis is constantly compromised due to degradation by NAD+ -dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors.
First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Introduction Replenishing nicotinamide mononucleotide (NMN) to raise the availability of nicotinamide adenine dinucleotide (NAD+) has been deemed as effective approach to prevent neurodegeneration in aging and pathological conditions including ALS, a fatal progressive neurodegenerative disorder with no known way to cure. The association of SOD1 and TDP-43 with ALS Cu/Zn-superoxide dismutase (SOD1) is the first identified protein associated with familial ALS. In most ALS cases, Transactive Response DNA Binding Protein 43 (TDP-43) pathology is frequently observed. Both SOD1 and TDP-43 have tight association with motor neuron degeneration in patients with ALS. Mutant SOD1 could affect the solubility/insolubility of TDP-43 through physical interactions. Mutant SOD1G93A and the fragment form of TDP-43 can exert synergistic effect to mediate toxic events in apoptosis. The protective effect of NMN on motor neurons NMN can increase the neurite length and complexity in mouse motor neurons and iPSC-derived human motor neurons overexpressing wild-type TDP-43/mutant hSOD1G93A. Meanwhile, it prevents the neuronal death and increased nitro-tyrosine immunoreactivity induced by trophic factor deprivation. In motor neurons overexpressing mutant hSOD1G93A, the neuroprotection conferred by NMN supplementation is mediated by a mechanism that involves an increase in glutathione content. However, this neuroprotective effect does not involve the alteration of glutathione content in non-transgenic or TDP-43 overexpressing motor neurons. The involvement of TDP-43 pathology in ALS NMN supplementation can confer axonal protection in motor neurons isolated from two dissimilar models of ALS, with and without involvement of TDP-43 pathology. Besides, NMN treatment correct the morphological changes induced by TDP-43 overexpression in motor neurons and boost the nuclear localization of TDP-43 and phosphorylated TDP-43, which favors its nuclear localization and averts the detrimental effects of TDP-43 overexpression on neurite length and complexity. Conclusion Supplementation of NAD+ precursor NMN can modulate neurite complexity and survival in motor neurons, showing great therapeutic potential in the context of ALS pathology. Reference [1] Hamilton HL, Akther M, Anis S, Colwell CB, Vargas MR, Pehar M. NAD+ precursor supplementation modulates neurite complexity and survival in motor neurons from ALS models. Antioxid Redox Signal. Published online March 19, 2024. doi:10.1089/ars.2023.0360 [2] Jeon GS, Shim YM, Lee DY, et al. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations. Mol Neurobiol. 2019;56(3):2007-2021. doi:10.1007/s12035-018-1218-2 BONTAC NMN BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BOMNTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website. .
1. Introduction On January 9, 2024, the expert team of selection organizing committee from Deloitte visited BONTAC, and presented the trophy of “China Life Sciences & Healthcare Rising Star” to BONTAC on site. By virtue of its unique and innovative technology in the field of coenzymes, professional R&D team with rich experience, and excellent performance in the industry of biosynthesis, BONTAC has stood out from the crowd and won the award of "Deloitte China Life Sciences & Healthcare Rising Star". 2. 2023 Deloitte China Life Sciences & Healthcare Rising Star Since the launch of “Deloitte China Life Sciences & Healthcare Rising Star” campaign by the end of June 2023, extensive attention has been attracted by the Chinese medicine and health industry. Following verification by site visit of the enterprises, 50 enterprises with prominent comprehensive strength are finally determined to be eligible, which are subjected to rigorous review of multiple dimensions such as financial asset valuation, founding team, technical innovation, market prospect, industrial rank, etc. The awarded enterprises in this selection campaign encompass the advanced enterprise in the niche areas of life sciences and healthcare, who comprehensively display their multiple innovation achievements in the field of life sciences and healthcare. The “Deloitte China Life Sciences & Healthcare Rising Star” selection campaign is a key subproject of Deloitt on the selection project of high-tech and fast-growing enterprises, aiming to recognize and award the outstanding enterprises who take the lead in their niche areas of life sciences and healthcare and have great growth potential. 3. The candidate enterprises must meet the the following criteria: * Business headquartered within China Mainland, Hong Kong or Macao. * Own leading technology and viable business models. * Have extensive growth potential with a leading position in their niche segments. 4. Current situation on Chinese medicine and health industry The technical innovation and product quality in Chinese medicine and health industry have continuously improved, which is driven by healthcare reform policies, emerging technologies and capital markets. In China, independent innovation has penetrated into all tracks of the major health industry, which greatly promotes the research and development of domestically produced innovative medicines and medical technologies. Substantial promising innovative enterprises has emerged and gradually gained recognition in the global market, ranking among the first echelon of global technological innovation. 5. About BONTAC BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. BONTAC adheres to independent innovation, with more than 160 invention patents. In the future, BONTAC will adhere to the innovation-driven concept, continue to increase investment in research and development, dig into the field of synthetic biology, and commit to developing more high-quality raw material products. At the same time, BONTAC will actively expand the international market, and work with global partners to promote the prosperous development of synthetic biology industry. In this era full of challenges and opportunities, BONTAC is confident to make greater contributions to the cause of human health.
On April 7th, 2023, KPMG China hosted the second Biotech Innovation 50 Enterprises award ceremony online, with CITIC Securities as a co-organizer. Bontac impressed the panel with its strong R&D capabilities and excellent performance in the synthetic biology sector, earning a spot on the "KPMG China 2023 Biotech Innovation Enterprises Top 50" list. The experts panel spent six months selecting the winners based on five core criteria: technology and product leadership, product pipeline richness and original research ratio, core management and R&D team background, capital market activity, and financial health. Bontac shines with its solid strength The "KPMG China 2023 Biotech Innovation Enterprises Top 50" award evaluated the enterprises from various aspects such as products, technology, team, finance, and funding. The selected enterprises are all high-quality enterprises with outstanding abilities in the biotech field, and being on the list is a great recognition. Bontac Deputy (fourth from the left) Bontac, as a leader in the synthetic biology industry, has always been at the forefront of R&D and production of coenzymes such as NMN, NADH and natural products such as ginsenoside Rh2, stevioside RD, etc. It has a strong comprehensive strength and a promising development potential that won the unanimous approval of the experts panel. From a scientific and technological point of view, Bontac has overcome several technical challenges, obtained more than 160 international patents and over 10 honorary qualifications, and owns more than 600 proprietary enzyme libraries. From the perspective of business scale, Bontac has three production bases that can achieve industrial production of hundreds of tons annually. Bontac also serves customers in more than 20 provinces in China and more than 60 countries. With the accordance of team configuration , Bontac has assembled representatives from four sides: scientists, engineers, entrepreneurs, and investors, empowering the enterprise from multiple dimensions. With the continuous upgrade of health consumption, the gradual release of new policy benefits related to medical regulation, and the rapid development of biopharmaceutical technology industry from a high-tech industry with great potential to a high-tech pillar industry. Biotech enterprises with potential represented by Bontac will leverage policy advantages and ride on market opportunities to integrate diverse resources in the ecosystem, support the development of China's biotech innovation enterprises, and enable win-win cooperation for the entire ecosystem. KPMG Biotech Innovation Enterprises Top 50 KPMG Awarding Ceremony KPMG China launched its first "Biotech Innovation Enterprises Top 50" award in 2021 and received widespread attention and support from the industry. KPMG invited distinguished representatives from research, industry, investment, and enterprise fields to share their insights on the hot topics and trends in biotech and explore the best practices for biotech innovation enterprises. The award also created a resource-matching platform for the selected biotech enterprises with potential, helping them seize the policy direction and capital market opportunities, increase their market visibility, and achieve organic growth from within and outside.